June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Matrix metalloproteinase inhibitor reverses endothelial-mesenchymal transformation
Author Affiliations & Notes
  • Wei-Ting Ho
    Ophthalmology, Far Eastern Memorial Hospital, New Taipei City, Taiwan
    Gradualte institute of clinical medicine, National Taiwan University, Taipei, Taiwan
  • I-Jong Wang
    Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan
    College of Medicine, National Taiwan University, Taipei, Taiwan
  • Footnotes
    Commercial Relationships Wei-Ting Ho, None; I-Jong Wang, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1168. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Wei-Ting Ho, I-Jong Wang; Matrix metalloproteinase inhibitor reverses endothelial-mesenchymal transformation. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1168.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Ex vivo culture of human corneal endothelial cells is often subjected to gradual mesenchymal transformation and loss of function. The present study was conducted to demonstrated the effect of matrix metalloproteinase inhibitor (MMPI) in reversing endothelial-mesenchymal transformation (EnMT) during ex vivo culture and in vivo.

Methods: Bovine corneal endothelial cells (BCECs) were cultured in medium with or without MMPI. Cell shape and protein localization were shown by immunofluorescence. MMP activity was monitored by fluorogenic substrate cleavage assay. Real-time PCR was used to determine RNA expression, and protein level was determined by Western blot. To determine the EnMT-reversing effect of MMPI in vivo, rat corneal endothelium cryo-injury model was used. Subsequent ultrasound biomicroscopy and histological examination were performed to evaluate corneal thickness. <br />

Results: During ex vivo culture, BCECs underwent EnMT and had upregulated MMP expression. Addition of MMPI to cultured BCECs decreased the level of EMT regulators, snail and slug. The phosphorylation and degradation of active beta-catenin was also accelerated after MMPI, which may result from decreased N-cadherin shedding and increased N-cadherin level on the cell membrane. In rat corneal endothelium cryo-injury model, intracameral injection of MMPI reversed EnMT and resulted in less corneal edema.<br />

Conclusions: MMPI can reverse EnMT and preserve the function of corneal endothelial cell both during ex vivo expansion and in vivo. This may offer a therapeutic target in regenerative medicine for the treatment of corneal endothelial dysfunctions.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×